Immunology

Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.

This article presents a systematic review of US health care disparities in biologics access across immunology (ie, rheumatology, dermatology, and gastroenterology) and a call to action.

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts.

A new review explores the complexities of cow's milk allergy in breastfed infants, including symptoms, diagnosis challenges, and the impact of maternal diet.

Many patients value conversations with their rheumatologists and oncologists more than just reading information from a website.

The lifestyle intervention included a whole-food plant-based diet, exercise, sleep, and stress management components.

High infection rates among younger adults suggest they either delay routine dental care and only seek treatment when conditions become severe, or face more barriers.

Researchers called for standardized health outcome descriptors to help bridge communication gaps in rheumatology care and improve shared decision-making.

Osteoarthritis leads the burden, projected to affect 50% of postmenopausal women by 2045.

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

Tocilizumab alone and in combination with methotrexate outperformed the latter drug in patients who did not adequately respond to conventional synthetic disease-modifying antirheumatic drugs.

Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study.

New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable treatment option for patients.

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and efficacy of nipocalimab for myasthenia gravis.

On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.

This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique histopathology and complications

Christopher Sayed, MD, discusses how hidradenitis suppurativa typically presents and looks forward, following the November approval of bimekizumab.

Generalized myasthenia gravis (gMG) is an autoantibody-driven chronic disease for which there is no cure.

Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on data from 2 phase 3 trials: BE OPTIMAL and BE COMPLETE.

With high biologic treatment failure rates common among patients who have hidradenitis suppurativa (HS), investigators set out to evaluate the potential of biomarkers to estimate potential treatment response.

For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurativa (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.

The Society for Pediatric Dermatology (SPD) Annual Meeting took place in Toronto, Canada, July 11-15, with our top coverage including the hot topics of combating misinformation and improving care for children with dermatologic conditions.

The 2024 American Academy of Dermatology conference was held in San Diego, California March 8 to 11.

Across 2024, top immunology news focused on ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis, highlighting studies on gut bacteria, radiographic progression, socioeconomic factors, and bimekizumab's persistent efficacy across multiple disease states.

In the continuation of our discussion with Chris Sayed, MD, University of North Carolina at Chapel Hill Department of Dermatology, he discusses the benefits of subcutaneous treatment of hidradenitis suppurativa, the chronic inflammatory skin condition.

Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients front and center.

On November 20, the FDA approved bimekizumab (Bimzelx; UCB Pharma) for use in patients with moderate to severe hidradenitis suppurativa.

This approval is the fifth overall for bimekizumab (Bimzelx; UCB Pharma) in the US, and they all have come in the last 13 months.

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).